Columnist Dagmar Munn shares how she finds ways to keep her anxiety and ALS fears in check with a few simple responses.

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

The FDA granted orphan drug designation to Sineugene Therapeutics' SNUG01, a first-in-class experimental gene therapy for ...

Clene is continuing to work with U.S. regulators on its plans to seek accelerated approval of CNM-Au8 for the treatment of ...

As her husband's ALS journey extends, columnist Kristin Neva considers finally "settling in," so to speak, by securing a better bed.

The manufacturing phase is expected to last about eight months, and will be followed by 4-6 months of regulatory preparation, including meetings with the U.S. Food and Drug Administration (FDA), ...